vTv Therapeutics Inc. (VTVT) vTv Therapeutics Inc. is a biopharmaceutical company in the clinical development stage, primarily focused on creating orally administered treatments, with a significant emphasis on diabetes. Its pipeline features lead candidates such as TTP399, an oral, small-molecule, liver-specific glucokinase activator targeting Type 1 diabetes. Another key investigational drug is HPP737, an oral phosphodiesterase type 4 (PDE4) inhibitor that does not cross the blood-brain barrier (non-CNS penetrant), designed to treat inflammatory conditions and psoriasis. Beyond these, vTv Therapeutics' broader clinical portfolio includes: TTP273, an oral small-molecule GLP-1 receptor agonist addressing postprandial glucose excursions in cystic fibrosis-related diabetes. HPP3033, which employs a non-electrophilic strategy to activate the Nrf2 pathway for chronic conditions linked to oxidative stress. Azeliragon, a RAGE antagonist being evaluated for inflammatory lung disorders, notably severe COVID-19, alongside pancreatic and breast cancers. HPP971, an Nrf2 activator aimed at renal diseases, developed in collaboration with pharmaceutical partners. Furthermore, vTv holds a licensing agreement with Reneo Pharmaceuticals, Inc. for the development and commercialization of its peroxisome proliferation-activated receptor delta agonist program, which features the compound HPP593. The company has also established various other licensing and research collaborations with entities such as Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., Newsoara Biopharma Co., Ltd., JDRF International, and Novo Nordisk A/S. Established in 2015, vTv Therapeutics is headquartered in High Point, North Carolina, and operates as a subsidiary of MacAndrews & Forbes Incorporated.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
vTv Therapeutics Inc. NASDAQ:VTVT Healthcare · Biotechnology
Mkt Cap $99.52M
Vol 0
$ Vol 0
RVOL 0
Earnings 0
Press Release
vTv Therapeutics Announces First Participant Randomized in Phase 2a Pilot Study Evaluating Cadisegliatin in Individuals with Type 1 Diabetes (T1D) Using Hybrid Closed-Loop (HCL) Insulin Delivery Systems
vTv Therapeutics announced the first participant has been randomized in its Phase 2a Hybrid CATT1 pilot study testing oral cadisegliatin in adults with type 1 diabetes who use hybrid closed-loop insulin delivery systems.
The ~40-person, six-week crossover study is designed to complement the already fully enrolled Phase 3 CATT1 trial, which only covered open-loop insulin users, and to inform design of future Phase 3 research in the AID segment.
Cadisegliatin holds FDA Breakthrough Therapy designation as a potential first-in-class oral adjunct to insulin, but no efficacy or safety data was released in this announcement.
• 5d ago AI analysis › Press Release
iOnctura appoints Paul Sekhri as Chair of its Board of Directors
iOnctura, a private clinical-stage oncology company, appointed Paul Sekhri as Chair of its Board effective immediately, replacing Dr. Mark Velleca.
Sekhri is a life sciences veteran who currently serves as Independent Chair of Apnimed (APMD), CEO of vTv Therapeutics (VTVT), and a director of Veeva Systems (VEEV).
The appointment carries no direct governance or operational impact on Apnimed; the filer is named only as one of Sekhri's existing board roles.
• 18d ago AI analysis › Press Release
vTv Therapeutics Announces Oral Presentation at Breakthrough T1D Clinical and Research Congress 2026
vTv Therapeutics presented survey research at the Breakthrough T1D Clinical & Research Congress 2026 highlighting hypoglycemia burdens among adults with type 1 diabetes using automated insulin delivery systems.
The dQ&A-conducted survey of 674 adults found roughly 54% of AID users experience at least one clinically meaningful hypoglycemia-related burden, a finding vTv says underscores the need for adjunctive therapies like cadisegliatin.
The release is promotional in nature and contains no new clinical data, regulatory milestones, or financial figures; cadisegliatin remains under investigation in a U.S. Phase 3 study with FDA Breakthrough Therapy designation.
• 22d ago AI analysis › Press Release
vTv Therapeutics Announces FDA Orphan Drug Designation for HPPD in Sickle Cell Disease
The FDA granted Orphan Drug Designation to vTv Therapeutics' HPPD, an oral first-in-class Nrf2/Bach1 modulator being investigated for sickle cell disease.
Preclinical studies in the Townes mouse model showed HPPD increased fetal hemoglobin and reduced oxidative stress and red blood cell sickling, with effects comparable to or exceeding hydroxyurea.
Management said the designation strengthens vTv's ability to advance strategic partnering discussions for HPPD while the lead asset cadisegliatin continues Phase 3 development in type 1 diabetes.
• 25d ago AI analysis › Press Release
vTv Therapeutics to Host Virtual KOL Event on Hypoglycemia in Type 1 Diabetes and the Cadisegliatin Phase 3 Program on October 20, 2026
vTv Therapeutics will host a virtual KOL event on October 20, 2026 at 2:30 PM ET covering hypoglycemia in type 1 diabetes and the cadisegliatin Phase 3 program.
Panelists include endocrinologists Schafer Boeder and Klara Klein plus T1D advocate Alisa Weilerstein, with a Q&A session following presentations.
Cadisegliatin, an oral liver-selective glucokinase activator with FDA Breakthrough Therapy designation, is being studied in the Phase 3 CATT1 trial with topline data expected in mid 2027.
• 26d ago AI analysis › Press Release ⚠ 2
vTv Therapeutics Announces Completion of Enrollment in Phase 3 CATT1 Study of Cadisegliatin in Type 1 Diabetes (T1D)
vTv Therapeutics completed enrollment in its Phase 3 CATT1 study of cadisegliatin as adjunctive therapy in type 1 diabetes, with 166 patients randomized.
CATT1 (NCT06334133) is a randomized, double-blind, placebo-controlled six-month trial testing 800 mg once- and twice-daily dosing, with a primary endpoint of level 2 and level 3 hypoglycemic events.
Cadisegliatin holds FDA Breakthrough Therapy designation and is a potential first-in-class oral liver-selective glucokinase activator; topline results are expected in mid 2027.
• 27d ago AI analysis › Press Release
vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
vTv Therapeutics granted 2,500 stock options to purchase common stock to a non-executive employee as a material inducement to employment under Nasdaq Listing Rule 5635(c)(4).
The options carry a $31.44 exercise price, vest over four years with 25% vesting on the one-year anniversary and the remainder quarterly over the following 36 months, and have a 10-year term under the 2026 Inducement Plan.
The grant is routine compensation housekeeping with no bearing on the clinical story: vTv's pipeline is led by cadisegliatin (TTP399), a liver-selective oral glucokinase activator in a US Phase 3 trial for type 1 diabetes that holds FDA Breakthrough Therapy designation.
• 1mo ago AI analysis › Press Release
vTv Therapeutics to Participate in September Investor Conferences
vTv Therapeutics announced management will participate in two investor conferences in September: the H.C. Wainwright 28th Annual Global Investment Conference and the 5th Annual ROTH Healthcare Opportunities Conference.
At H.C. Wainwright in New York on September 16, management will host a fireside chat from 10:00-10:30 AM ET plus one-on-one meetings; ROTH one-on-ones follow on September 29.
The release reiterates that the company's pipeline is led by cadisegliatin, a potential first-in-class oral glucokinase activator in a U.S. Phase 3 study for type 1 diabetes, with FDA Breakthrough Therapy designation. No new clinical or financial data was disclosed.
• 1mo ago AI analysis › Press Release
vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
vTv Therapeutics granted 2,500 stock options to a new non-executive employee as an employment inducement under Nasdaq Listing Rule 5635(c)(4).
The options have an exercise price of $31.48 per share and vest over a four-year period, with 25% vesting after one year and the remainder vesting quarterly.
This filing is a standard corporate governance disclosure regarding compensation and does not alter the company's clinical or operational status.
• 2mo ago AI analysis › Press Release
vTv Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
vTv Therapeutics confirmed it expects to complete enrollment in the Phase 3 CATT1 trial of cadisegliatin for type 1 diabetes in Q3 2026, with a Phase 2a hybrid closed-loop trial initiating before year-end.
The company reported $86.6 million in cash as of June 30, 2026, sufficient to fund operations through the anticipated topline data readout.
Q2 net loss was $13.1 million, or $1.05 per share, with R&D expenses increasing to $8.8 million driven by the Phase 3 trial.
• 2mo ago AI analysis › Press Release
vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
vTv Therapeutics granted 23,500 stock options to two new non-executive employees as a material inducement to employment under Nasdaq Rule 5635(c)(4).
The options have a weighted average exercise price of $31.95 per share, vesting over four years with a one-year cliff and quarterly vesting thereafter.
The company continues to focus on cadisegliatin, a Phase 3 oral therapy for type 1 diabetes.
• 3mo ago AI analysis › Press Release
vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
vTv Therapeutics granted 12,500 stock options to two new non-executive employees as a material inducement to employment under Nasdaq Listing Rule 5635(c)(4).
The options carry a weighted average exercise price of $34.15 per share and vest over four years, with 25% vesting on the first anniversary and the remainder vesting quarterly thereafter.
vTv Therapeutics is a late-stage biopharmaceutical company focused on cadisegliatin, a potential first-in-class oral therapy for type 1 diabetes currently in a Phase 3 trial.
• 4mo ago AI analysis › Press Release
vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
vTv Therapeutics granted 2,500 stock options to a non-executive employee as a material inducement to employment.
The options have an exercise price of $34.30, which matches the closing stock price on June 1, 2026, and vest over four years.
This disclosure satisfies Nasdaq Listing Rule 5635(c)(4) requirements for at-the-money induement grants and represents negligible dilution.
• 4mo ago AI analysis › Press Release ● Major
vTv Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
globenewswire.com • 5mo ago Press Release
vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com • 5mo ago Press Release
vTv Therapeutics to Participate in Upcoming May Investor Conferences
vTv Therapeutics announced that management will participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference on May 19 and the Alliance Global Partners Healthcare Company Showcase on May 20.
The company's lead asset, cadisegliatin, is a potential first-in-class oral adjunctive therapy for type 1 diabetes currently in a U.S. Phase 3 trial with Breakthrough Therapy designation.
Webcasts of the fireside chats will be available on the company's website.
• 5mo ago AI analysis › Press Release
vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com • 6mo ago Press Release
vTv Therapeutics to Participate in the 38th Annual ROTH Conference
globenewswire.com • 7mo ago Press Release ● Major
vTv Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
globenewswire.com • 7mo ago 
